Literature DB >> 26482169

Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".

Nuggehally R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26482169     DOI： 10.1007/s40262-015-0335-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  6 in total

1.  Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.

Authors:  Luc Van Rompaey; René Galien; Ellen M van der Aar; Philippe Clement-Lacroix; Luc Nelles; Bart Smets; Liên Lepescheux; Thierry Christophe; Katja Conrath; Nick Vandeghinste; Béatrice Vayssiere; Steve De Vos; Stephen Fletcher; Reginald Brys; Gerben van 't Klooster; Jean H M Feyen; Christel Menet
Journal:  J Immunol       Date:  2013-09-04       Impact factor: 5.422

Review 2.  Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.

Authors:  Richard J Riese; Sriram Krishnaswami; Joel Kremer
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-08       Impact factor: 4.098

3.  Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Authors:  Kamran Ghoreschi; Michael I Jesson; Xiong Li; Jamie L Lee; Sarbani Ghosh; Jason W Alsup; James D Warner; Masao Tanaka; Scott M Steward-Tharp; Massimo Gadina; Craig J Thomas; John C Minnerly; Chad E Storer; Timothy P LaBranche; Zaher A Radi; Martin E Dowty; Richard D Head; Debra M Meyer; Nandini Kishore; John J O'Shea
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

4.  Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

Authors:  Claude Haan; Catherine Rolvering; Friedrich Raulf; Manuela Kapp; Peter Drückes; Gebhard Thoma; Iris Behrmann; Hans-Günter Zerwes
Journal:  Chem Biol       Date:  2011-03-25

Review 5.  Janus kinase inhibitors in autoimmune diseases.

Authors:  John J O'Shea; Apostolos Kontzias; Kunihiro Yamaoka; Yoshiya Tanaka; Arian Laurence
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

6.  Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

Authors:  Florence Namour; Paul Matthias Diderichsen; Eugène Cox; Béatrice Vayssière; Annegret Van der Aa; Chantal Tasset; Gerben Van't Klooster
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447
  6 in total
  1 in total

1.  Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection".

Authors:  Florence Namour
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.